Morbidity and mortality of essential arterial hypertension treated in Chile: a 15 years' follow-up study Morbimortalidad de la hipertensión arterial esencial tratada en Chile: seguimiento a 15 años.
Author
dc.contributor.author
Román Román, Pablo
Author
dc.contributor.author
Basso,
Author
dc.contributor.author
Cuevas,
Author
dc.contributor.author
Martínez Martínez, Regina
Author
dc.contributor.author
Cumsille,
Admission date
dc.date.accessioned
2019-01-29T15:47:39Z
Available date
dc.date.available
2019-01-29T15:47:39Z
Publication date
dc.date.issued
1991
Cita de ítem
dc.identifier.citation
Revista medica de Chile, Volumen 119, Issue 7, 2018, Pages 744-752
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/162437
Abstract
dc.description.abstract
In order to establish morbidity and mortality in treated patients with essential hypertension, a prospective study was started in 1974. 714 patients were followed for 15 years. Admission criteria included diastolic blood pressure over 95 mmHg during one month on placebo, absence of malignant or accelerated hypertension and no recent (6 month) cardiovascular complication. According to target organ damage, 51% of patients were in WHO stage I, 35% in stage II and 14% in stage III. There were 342 males and 372 females, with mean age 58.7 +/- 9.8 years. Mean initial blood pressure was 181/110 +/- 12/8.9 mmHg. Treatment schedules included diuretics alone (23%), beta blockers alone (32%), diuretic and betablocker (38%), combined therapy with vasodilators (9%) and other forms of therapy (5%). 75 subjects failed to comply with therapy but were maintained in the analysis (intention to treat). A significant reduction in blood pressure was observed in the group as a whole (154/93 +/- 7/9 mmHg). Su
Morbidity and mortality of essential arterial hypertension treated in Chile: a 15 years' follow-up study Morbimortalidad de la hipertensión arterial esencial tratada en Chile: seguimiento a 15 años.